Amgen buying out joint venture Kirin-Amgen for $780 million
Amgen, the biotech giant based in Thousand Oaks, announced that it would buy out joint venture Kirin-Amgen, which was created to develop white blood cell booster Neupogen among other projects, for $780 million. The joint venture holds intellectual property rights for Neupogen, Neulasta, Aranesp, Nplate and brodalumab. In addition to the cash deal, Amgen will Read More →
Amgen product sales slip but income stays steady
Net income at biotech giant Amgen stayed flat for the third quarter, despite a slight downtick in revenues to $5.8 billion, the company reported Oct. 25. Product sales saw a slight decline, including Neupogen, Epogen and its blockbuster rheumatoid arthritis drug Enbrel, which fell 6 percent, but net income stayed steady at a little more Read More →
Ventura County economic development plan approved
Ventura County’s Board of Supervisors has approved the first economic development plan in the history of the county. The board voted 5-0 to approve the countywide “Economic Vitality Strategic Plan” at its board meeting on Oct. 24. Officials said the plan was the product of four public sessions and was designed to “foster economic growth Read More →
Biotech giant Amgen to pay dividend on Dec. 8
Biotech giant Amgen announced Oct. 24 that it would pay a $1.15 dividend for its fourth quarter of fiscal 2017. Stockholders of record for the Thousand Oaks-based company at the end of day on Nov. 17 will receive the dividend on Dec. 8.
Ventura County has need for faster broadband speed
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Upscale apartment complex under construction in SLO
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen settles with AbbVie over Humira biosimilar litigation
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
